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ABSTRACT
BACKGROUND: Cirrhotic patients undergoing liver transplantation are at risk of cardiac complications. Brain 
natriuretic peptide (BNP) and amino terminal brain natriuretic peptide (NT-BNP) are used in cardiac risk stratification. 
Their significance in predicting mortality risk in cirrhotic patients during or after liver transplantation is unknown. 
We conducted a systematic review and meta-analysis to answer this question. METHODS: An electronic search 
of EMBASE, MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews 
(2005–September 2016), Google Scholar, and study bibliographies was conducted. Study quality was determined, 
and demographic and outcome data were gathered. Random effects meta-analyses of mortality-based BNP and 
NT-BNP level or presence of post-transplant heart failure were conducted. RESULTS: Seven studies including 2,010 
patients were identified. Demographics were similar between patients with high or low BNP or NT-BNP levels. 
Hepatitis C was the most prevalent etiology of cirrhosis (38%). Meta-analysis revealed a pooled relative risk of 3.1 
(95% CI 1.9% to 5.0%) for post-transplant mortality based on elevated BNP or NT-BNP level. Meta-analysis also revealed 
a pooled relative risk of 1.6 (95% CI 1.3% to 2.1%) for post-transplant mortality if patients had demonstrated post-
transplant heart failure. CONCLUSIONS: Our analysis suggests that BNP or NT-BNP measurement may help in risk 
stratification and provides data on post-operative mortality in cirrhotic patients undergoing liver transplantation. 
Discriminatory thresholds are higher in cirrhotic patients relative to prior studies with non-cirrhotic patients. 
However, the number of analyzed studies is limited, and our findings should be validated further through larger, 
prospective studies.
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INTRODUCTION
Cirrhotic patients undergoing liver transplanta-
tion are at high risk of death from cardiac com-
plications even in the absence of any known 
underlying cardiac disease (1,2). In a national 
database study, major adverse cardiac events 
(MACE) occurred in 11% of liver transplant re-
cipients and had a negative impact on survival 
(3). Peri-transplant heart failure and myocardial 
depression have also been found to correlate with 
increased post-operative morbidity and mortal-
ity (4–6). High-risk features for MACE include 
pre-transplant atrial fibrillation and stroke (3). 
Regardless, algorithms or biomarkers commonly 
used for peri-operative risk stratification in other 
populations and surgical settings have not been 
thoroughly investigated in cirrhotic patients and 
liver transplantation.
Brain natriuretic peptide (BNP) and amino ter-
minal brain natriuretic peptide (NT-BNP) are bio-
markers commonly used in the management of 
congestive heart failure (7). In cirrhotic patients, 
elevated BNP or NT-BNP may reflect systolic 
dysfunction, left ventricular hypertrophy with 
subsequent diastolic dysfunction, and increased 
pulmonary artery pressures with resulting right 
ventricular overload (8,9,10,12). Elevated BNP 
or NT-BNP also seems to reflect disease severity, 
with correlations to presence of ascites, decreased 
synthetic function, increased hepatic venous pres-
ence gradient, and increased Child–Pugh and 
model for end-stage liver disease (MELD) scores 
(13). Elevated BNP or NT-BNP has also been im-
plicated as an independent predictor of mortality 
in advanced cirrhosis (14). This cardiac dysfunc-
tion in cirrhotic patients has been termed cirrhotic 
cardiomyopathy (CCM), although its clinical sig-
nificance remains unknown (15). It has been sug-
gested that because of CCM, large increases in 
cardiac pre-load such as that experienced upon 
perfusion of a newly transplanted liver, predis-
poses these patients to cardiac events and sub-
sequent mortality even in the absence of other 
cardiac disease (16).
Elevated levels of pre-operative BNP or NT-
BNP are commonly used to risk stratify patients 
and predict cardiac events or mortality after both 
cardiac and non-cardiac surgery (20). However, 
as mentioned earlier, cirrhotic patients with CCM 
may demonstrate falsely elevated BNP or NT-BNP 
levels. Cirrhotic patients also display high rates of 
other comorbidities that may elevate BNP levels 
such as hyper-dynamic circulation, renal impair-
ment, hypoxemia, and sepsis (17). Falsely elevated 
levels of cardiac biomarkers may not correlate 
with peri-operative risk (18). Alternatively, BNP 
levels in cirrhotic patients may be falsely low be-
cause of the prevalent use of diuretic medications 
such as spironolactone (19). Previous systematic 
reviews and meta-analyses of BNP or NT-BNP 
use for risk stratification have not included large 
numbers of cirrhotic patients or studies involving 
liver transplantation (20,21). Therefore, the clinical 
measurement of pre-operative BNP or NT-BNP in 
the setting of cirrhosis and liver transplantation re-
mains difficult to interpret.
We conducted a systematic review and meta-
analysis to understand whether these commonly 
used biomarkers could have application in pre-
dicting peri– and post–liver transplant mortality 
or cardiovascular morbidity in cirrhotic patients. 
In addition, we wanted to define whether the 
presence of cirrhosis and associated comorbidi-
ties altered the clinical utility of these tests in this 
population.
METHODS
An electronic search of EMBASE (1974–September 
2016), MEDLINE (1946–present), EBM Reviews–
Cochrane Central Register of Controlled Trials 
(1946–August 2016), EBM Reviews–Cochrane 
 Database of Systematic Reviews (2005– September 
2016), and Google Scholar was conducted. We 
also searched bibliographies of relevant studies 
and the ‘related articles’ link to identify studies 
that may have been missed in database searches. 
The search strategy was planned with the help 
of a medical librarian. Medical subject head-
ings and free-text terms included combinations 
of ‘brain natriuretic peptide,’ ‘b-type peptide,’ 
‘natriuretic peptide, brain,’ ‘bnp,’ ‘nt-bnp,’ ‘nt-
probnp,’ ‘probnp,’ ‘liver transplantation,’ and 
‘liver transplant.’
The titles of all articles were assessed for rele-
vance to the study question, and relevant articles 
were retrieved and abstracts screened in detail. The 
articles whose abstracts were pertinent were fur-
ther evaluated. Our primary outcomes of interest 
were peri- and post-transplant all-cause mortality. 
Our secondary outcome of interest was peri- and 
post-transplant cardiovascular complications. We 
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on NT–proBNP or BNP levels of cirrhotic patients, 
stratified cirrhotic patients into groups on the basis 
of the presence of elevated BNP or post-transplant 
heart failure, and provided post-transplantation 
outcome data on these cirrhotic cohorts. We ex-
cluded studies of children (aged younger than 
19  years), non-human experiments, studies of 
multi-organ transplants, case reports, and studies 
that did not provide adequate BNP, NT-BNP, or 
outcome data. Both screening of identified studies 
and assessment for eligibility were performed in 
duplicate by two investigators (DC, AY) indepen-
dently. Any disagreement between investigators 
was resolved by consensus.
Data were extracted independently by two 
investigators into a Microsoft Excel spreadsheet 
(Microsoft, Redmond, WA). The following data 
were extracted: year of publication, study de-
sign, number of patients included, baseline pa-
tient demographics, MELD and Child–Pugh 
scores immediately before transplant, cirrhosis 
etiology, cirrhosis complications, comorbidities, 
medications used, laboratory parameters, he-
modynamic parameters, and echocardiographic 
data. Post-transplant data included mortality, 
cardiac events, and other complications of inter-
est. When the data were not available from the 
article, we made an effort to email the authors di-
rectly for additional information. In case of non-
response, an additional reminder email was sent. 
The quality of the studies was assessed using the 
Newcastle-Ottawa scale for observational studies 
with high-quality studies scoring above 6 (22).
For patient demographics, we calculated 
weighted means and standard deviations when 
applicable. For each study we calculated the in-
cidence death rate or the incidence rate (IR) of 
cardiovascular complications after liver trans-
plantation. We obtained the incidence relative risk 
(IRR) and 95% confidence interval by comparing 
groups with high versus low pre-treatment BNP 
or NT-BNP values.
Heterogeneity between studies was assessed by 
using the I2 statistic with a cut-off value of 50% and 
the chi-square test with a P-value less than 0.10 to 
define a significant degree of heterogeneity. Before 
analysis, we decided that a meta-analysis using a 
random-effects model was going to be used in the 
absence of significant heterogeneity. In the pres-
ence of significant heterogeneity, individual study 
results would have been presented, but we would 
not pool their effects. Evidence of publication bias 
was assessed by applying the Egger test to funnel 
plots. All statistical analyses were performed using 
Stata 14.2 (StataCorp, College Station, Texas)
RESULTS
Our search yielded 192 records. After removal of 
duplicates, we were left with 177 records to screen. 
We ultimately excluded 147 records, leading to 30 
full-text reviews. Of these 30, 7 articles met all cri-
teria and were used for both qualitative and quan-
titative analysis (Figure 1).
Study characteristics
We identified seven studies for analysis (23–29). 
Four of these studies were prospective and three 
were retrospective in nature. All studies were 
single centre. Studies stratified their patient co-
horts in one of two manners: either by a high 
BNP–NT-BNP versus a low BNP–NT-BNP or by 
the development of post-transplant heart failure 
versus no development of post-transplant heart 
failure. Sample sizes ranged from 40 to 970 pa-
tients. The majority of patients were transplanted 
for underlying cirrhosis. Study characteristics are 
detailed in  Table 1. One study excluded patients 
with prior history of non-cirrhotic cardiac dis-
ease (29). Primary outcomes consisted of either 
mortality or development of heart failure or other 
cardiac events (heart failure, myocardial infarc-
tion, cardiac arrest, life-threatening arrhythmia). 
Follow-up times ranged from 6 months to more 
than 5 years. Assessment of quality by Newcastle-
Ottawa Scale demonstrated scores of 7 or 8 for all 
studies (Table 2). Specifics of inclusion and exclu-
sion criteria and outcomes may be found in Sup-
plementary Table 1.
Patient demographics
A total of 2,010 patients were identified. Of these 
patients, 335 belonged to high BNP–NT-BNP or 
heart-failure cohorts (218 high BNP, 117 heart 
failure), whereas 1,675 belonged to low BNP–NT-
BNP or no-heart-failure cohorts (731 low BNP, 
944 no heart failure). Studies reported statistics 
in both means and medians, and as such care was 
taken to record data as presented and make ap-
propriate calculations. Weighted mean patient 
age was 52.5 (SD 9.3) years. Weighted mean BMI 
was 25.4 (SD 1.9). The proportion of male pa-
tients ranged from 51.5% to 81.3% and was simi-
lar between cohorts in all studies. Weighted mean 
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-Cohorts not stratified by BNP
-Pediatric studies
-Multi-organ transplant
-Data overlap with newer
studies from same instution or
author
Figure 1: Results of systematic review search algorithm
Etiology of underlying cirrhosis was reported in 
six studies (Table 3). Hepatitis C was the most 
prevalent etiology of cirrhosis (38%). Other 
prevalent etiologies included alcohol (23%), he-
patocellular carcinoma (7%), and non-alcoholic 
steatohepatitis (NASH; 5%). There were 694 pa-
tients on diuretics and 439 on aldosterone. Specif-
ics about patient demographics and medication 
use can be found in the supplementary data 
 (Supplementary Table 2).
BNP and NT-BNP measurements
One study measured NT-BNP (29), and the remain-
der measured BNP levels (23–28). Five studies re-
corded pre-transplant BNP–NT-BNP levels, one 
recorded intra-operative levels, and one recorded 
levels on post-operative day 1. Studies by Toussaint 
et al, Kim et al, and Saner et al stratified patient co-
horts by BNP–NT-BNP levels (23, 25, 27). Toussaint 
et al and Kim et al determined the optimal BNP 
level that predicted 180-day intensive care unit 
(ICU) and 1-year mortality, respectively, by receiver 
operating characteristic curve with areas under 
curve of 0.79 (0.66–0.93) and 0.694 (0.652–0.733; 23, 
25). Saner et al pre-specified BNP values of less than 
391 pg/mL and more than 391 pg/mL on the basis 
of prior experimental evidence suggesting that lev-
els less than 391 pg/mL effectively ruled out heart 
failure (30). Studies by Qureshi et al and Casciato et 
al stratified patient cohorts on the basis of presence 
of heart failure (24, 26). Pre-operative BNP levels 
were higher in groups that developed heart failure 
in both the Qureshi et al study (120.3 [SD 139.3] 
pg/mL versus 61.5 [SD 68.4] pg/mL; P < 0.001) and 
Casciato et al study (598.3 [interquartile range {IQR} 
366.7] pg/mL versus 115.0 [IQR 103.5]  pg/mL; 
P < 0.001). The study by Therapondos et al strati-
fied patients on the basis of presence of post-
operative pulmonary edema and noticed higher 
pre- operative BNP levels in those who developed 
edema (75 [SD 24] vs. 42 [SD 6] pg/mL; P < 0.043; 28). 
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Table 1: Characteristics of studies included in meta-analysis
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1 y survivors vs. 1 y 
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POD1 POD1 BNP < 391 vs. 
POD1 BNP > 391†
POD1 BNP 391–567 
vs. POD1 BNP > 
567































BNP > 2,000 vs. 
BNP < 2,000†





* Non-cirrhotic patients in this study were not transplanted
† Cohorts used in meta-analysis
‡ Outcomes used in meta-analysis
Abbreviations: BNP = brain natriuretic peptide; ICU = intensive care unit; NR = not reported; NT-BNP = amino terminal brain natri-
uretic peptide; OLT = orthotopic liver transplant; POD = post-operative day
different cohorts of cirrhotic patients; rather, they 
noticed higher pre-operative NT-BNP levels in 
cirrhotic patients than in healthy controls with no 
history of liver disease (1,759 (SD 1,154) pg/mL 
versus 856 (SD 123) pg/mL; P < 0.05; 29). In a 
sub-group, the study by Bernal noted more post-
operative cardiac events in a group that exhibited 
NT-BNP levels higher than 2,000 pg/mL (specifics 
of cardiac events are detailed in the next section). 
The determination of the 2,000 pg/mL  cut-off 
value was made on the basis of European Society 
of Cardiology guidelines that provide evidence 
that a NT-BNP value of more than 2,000 pg/mL 
in the presence of clinical signs and symptoms of 
heart failure is strongly suggestive of chronic heart 
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cohorts, determination of cut-off values, and defi-
nitions of heart failure may be found in Supple-
mentary Tables 3–5.
Mortality
Five of the seven studies reported mortality data 
based on BNP–NT-BNP level (Table 4). In the study 
by Toussaint et al, 17.8% of patients with BNP levels 
more than 155 pg/mL died by 6 months compared 
with 3.7% with BNP less than 155 pg/mL (23). In 
patients with a MELD score more than 25, 29.3% 
of patients with BNP more than 155 pg/mL died 
at 6 months compared with only 6.7% with BNP 
 levels less than 155 pg/mL. Of patients with BNP 
levels more than 155 pg/mL, 15.1% died in the ICU 
during the immediate post-operative period com-
pared with 14.9% with BNP less than  155 pg/ mL. 
Similarly, in those with a MELD score more 
than 25, 26.8% with BNP more than 155 pg/mL 
died in the ICU compared with 0.0% with BNP 
less than 155 pg/mL. In this study, each 50 pg/mL 
increase in BNP, after adjustment for MELD score, 
was associated with significant hazard ratios of 
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Ascertainment of 
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Secured records X X X X X X X
Outcome of inter-
est not present at 
study start?
Alive at study start X X X X X X X
Study controls for 
age and sex?
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Total score 8 8 8 8 7 7 7
Abbreviations: BNP = brain natriuretic peptide; MELD = model for end-stage liver disease 









Primary biliary cirrhosis 3
Primary sclerosing cholangitis 4
Cryptogenic or other 13
1.035 for both ICU and 6-month mortality (1.022–
1.049; P < 0.001). In the study by Saner et al, 52.0% 
of patients with BNP levels more than 391 pg/ mL 
died in hospital compared with 15.2% with BNP 
less than 391 pg/mL (27). In the study by Kim et al, 
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died at 1 year compared with 5.9% with BNP less 
than 136 pg/mL (25). LogBNP was associated with 
a significant 1-year all-cause mortality hazard ratio 
of 2.657 (P < 0.001). In the study by Casciato et al, 
9.1% of patients who developed post- operative 
heart failure died at 6  months compared with 
5.0% who did not develop post- operative heart 
failure (26). In the study by Qureshi et al, 42.9% 
of  patients who developed post- operative heart 
failure died compared with 26.1% who did not 
 develop post-operative heart failure (24).
We tallied mortality events by studies that pro-
vided BNP–NT-BNP or heart failure cohorts. Ex-
amining studies that separated their cohorts on the 
basis of high or low BNP–NT-BNP, we found a total 
of 50 mortality events for 200 patients (25.0%) who 
had high BNP–NT-BNP compared with 50 mortality 
events for 689 patients (7.3%) who had low BNP–NT-
BNP. When examining studies that separated their 
cohorts on the basis of presence of post-operative 
heart failure, we found a total of 43 mortality events 
for the 109 patients (39.4%) who developed post-
operative heart failure compared with 230 mortality 
events for the 912 patients (25.2%) who did not de-
velop post-operative heart failure (Table 3).
We then performed two meta-analyses. The 
first analysis consisted of three studies that strati-
fied cohorts into high BNP–NT-BNP versus low 
BNP–NT-BNP groups with the outcome of inter-
est being all-cause mortality (23, 25, 27; Figure 2). 
A pooled IRR of 3.1 (95% CI 1.9% to 5.0%) was 
demonstrated. Heterogeneity did not preclude 
pooling (chi-square P = 0.179; I2 = 41.9%). The sec-
ond analysis consisted of two studies that strati-
fied cohorts into presence of post-transplant heart 
failure versus no post-transplant heart failure with 
all-cause mortality as the outcome of interest (24, 
26; Figure 3). A pooled IRR of 1.6 (95% CI 1.3% to 
2.1%) was demonstrated. Heterogeneity did not 
preclude pooling (chi-square P = 0.930, I2 = 0.0%). 
Table 4: Mortality events by study and cohort
Study and cohort Patients, n Mortality, no. of patients Incidence, % Follow-up time
Toussaint et al (23)
BNP > 155 73 13 17.8 6 mo
BNP < 155 134 5 3.7
Saner et al (27)
BNP > 391 25 13 52.0 In hospital
BNP < 391 132 20 15.2
Kim et al (25)
BNP > 136 102 24 23.5 1 y
BNP < 136 423 25 5.9
Casciato et al (26)
Post-op HF 11 1 9.1 6 mo
No post-op HF 40 2 5.0
Qureshi et al (24)
Post-op HF 98 42 42.9 5.3 (SD 3.4) y
No post-op HF 872 228 26.1
Totals:
High BNP 200 50 25.0
Low BNP 689 50 7.3
Post-op HF 109 43 39.4
No post-op HF 912 230 25.2
Note: BNP measured in pg/mL
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Figure 2: Meta-analysis of post-operative mortality based on peri-operative BNP level


















Overall (I-squared = 0.0%, p = 0.930)
Note: Weights are from random effects analysis
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Given the small number of studies included in this 
meta-analysis, assessment of publication bias by 
funnel plot and Egger’s test was not appropriate.
Post-operative cardiac events
Five studies reported on post-operative heart failure, 
cardiac events, or both. Therapondos et al  reported 
the development of pulmonary edema in 8 of 40 
 patients undergoing liver transplantation and noted 
that those with pulmonary edema had higher pre- 
operative BNP levels, as mentioned earlier (28). 
 Studies by Casciato et al and Qureshi et al noted higher 
BNP levels in those who developed post- operative 
heart failure, as noted above in the BNP and NT-BNP 
measurements section (24, 26). Qureshi et al reported 
that BNP more than 50 pg/mL was associated with 
development of post-operative systolic heart failure 
(hazard ratio [HR] 2.04 [95% CI 1.21% to 3.70%]; P = 
0.02; 24) but not with post- operative diastolic heart 
failure (HR 1.01 [95% CI 0.42% to 2.43%]; P = 0.98). 
Qureshi et al. also noted six intra-operative cardiac 
arrests; five of these patients developed systolic dys-
function over a period of 5 years; only one patient 
developed immediate post- operative systolic failure. 
Intra-operative cardiac arrest was significantly asso-
ciated with development of post- operative systolic 
heart failure (HR 16.39 [95% CI 4.32% to 62.5%]; P < 
0.001). Casciato et al, after  adjusting for blood pres-
sure, left ventricular ejection fraction, and left atrial 
diameter, also reported a significant association of el-
evated pre-operative BNP with development of post-
operative acute heart failure (HR 1.95 [95% CI 1.13% 
to 3.34]; P = 0.016). 
Saner et al noted two post-operative incidences 
of cardiogenic shock in a subset of patients who 
had BNP greater than 567 pg/mL but none in those 
with BNP less than 567 pg/mL (27). Bernal et al 
noted that 37% of patients with NT-BNP greater 
than 2,000 pg/mL developed a non-specified car-
diac event compared with 9% of those with BNP 
less than 2,000 pg/mL (P = 0.008; 29). We calculated 
an IRR of 7.9 (95% CI 1.8% to 34.7%; P = 0.006) for 
post-transplant cardiac events on the basis of ele-
vated BNP from that study. Because of heterogene-
ity of reporting methods and patient stratification 
for post-operative cardiac events, a complete meta-
analysis could not be carried out.
DISCUSSION
Liver transplantation a carries high a risk of 
post- operative MACE and mortality. BNP and 
pre-NT-BNP are commonly assessed in pre- 
operative settings to help stratify cardiac risk, but 
specific analysis in liver transplantation remains 
sparse. There is also concern that BNP or NT-BNP 
elevation in cirrhotic patients as a result of CCM or 
other comorbidities may not truly reflect post-op-
erative risk. Although the number of studies in this 
analysis are limited, our results suggest that despite 
these concerns, BNP or NT-BNP measurement may 
be a viable method to identify those individuals at 
higher risk of mortality after liver transplantation.
B-type natriuretic peptides, mortality, and 
cardiac events
Meta-analysis of three studies demonstrated in-
creased risk of death on the basis of elevated peri-
operative BNP or NT-BNP (IRR 3.1 [95% CI 1.9% to 
5.0%])(23,25,27). These findings are in agreement 
with previous analyses of B-type natriuretic  peptides 
that associated pre-operative elevations with post- 
operative mortality in non-cardiac, cardiac, and vas-
cular surgery (20,21,32,33). It is important to note 
that the majority of studies included in these previ-
ous analyses examined mortality within 30 days of 
surgery, whereas our included studies tallied mor-
tality at 180 days (23), 1 year (25), and early in hospi-
tal without a time frame (27). However, the analysis 
in vascular patients also included a subgroup analy-
sis of two studies demonstrating an association of 
180-day mortality with elevated pre-operative BNP 
(HR 3.31, 95% CI 2.1% to 5.24%; 33–35). The meta- 
analysis of BNP in cardiac surgery patients also 
 included several studies extending far beyond 30 
days, with one of the included studies reporting out-
comes at a mean follow-up of 4.3 years (32). A caveat 
must be taken into account: a longer time frame for 
mortality outcomes necessitates a lower BNP–NT-
BNP discriminatory threshold (36,37).
We also performed a meta-analysis of two stud-
ies that demonstrated increased risk of death on 
the basis of post-transplant heart failure (IRR 1.6 
[95% CI 1.3% to 2.1%]) (24,26). Pre-operative BNP 
in both studies was significantly higher in those 
patients who developed post-operative heart fail-
ure (Qureshi et al, 120.3 [SD 139.3] pg/mL versus 
61.5 [SD 68.4 pg/mL]; P < 0.001; Casciato et al, 598.3 
[IQR 366.7] pg/mL versus 115.0 [IQR 103.5] pg/mL; 
P  <  0.001). Median time to onset of heart failure 
was 101.5 days in the Qureshi et al study, and 7 
of the 11  patients who developed heart failure in 
the  Casciato et al study presented within 14 days 
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our study, and we did not necessarily identify all 
studies that directly evaluated association of post-
transplant heart failure with mortality. For example, 
a study not included in our analysis because of the 
lack of BNP data associated peri-transplant heart 
failure with peri-transplant mortality (OR 15.11 [95% 
CI 1.76% to 129.62%]) (5). Regardless, the elevation 
of pre-operative BNP in those who developed heart 
failure and its association with mortality again sug-
gests the validity of risk stratification with BNP in 
cirrhotic patients undergoing liver transplantation.
Reporting of post-operative cardiac events in 
our included studies, excluding heart failure, was 
sparse. Only one study reported raw data specifi-
cally on elevated BNP and post-transplant cardiac 
events, with a calculated IRR of 7.9 (95% CI 1.8% 
to 34.7%) (29). It is interesting that this study ex-
cluded patients with known cardiac disease, pos-
sibly implicating CCM in the development of 
post-operative events. There was also association of 
pre-operative BNP elevation with development of 
post-operative systolic heart failure (HR 2.04 [95% 
CI 1.21% to 3.70%]; P = 0.02) in the Qureshi et al 
study and post-operative acute heart failure (HR 
1.95 [95% CI 1.13% to 3.34%]; P = 0.016) in the Cas-
ciato study (24,26). These studies did not exclude 
patients with previous cardiac disease, and as such 
the etiology of their heart failure could be quite 
varied. Unfortunately, the lack of data specific to 
cardiac events does not allow us to comment on the 
association between peri-operative BNP–NT-BNP 
elevation and immediate post-operative events.
Taken together, these meta-analyses suggest 
that peri-operative elevations in BNP–NT-BNP are 
associated with increased risk of mortality in cir-
rhotic patients undergoing liver transplantation. 
It is possible that post-operative heart failure may 
serve as the primary driver of mortality. However, 
it is important to note that the number of studies in 
this area are quite limited, and they are varied in 
their methodology. Thus, rather than making firm 
conclusions, we suggest that our results are ex-
ploratory and should be further assessed through 
larger, prospective trials.
Non-cardiac mechanisms for B-type peptide 
alterations in cirrhotic patients
Falsely high levels of peri-operative natriuretic 
peptides unrelated to underlying cardiac disease 
may not necessarily reflect peri-operative risk 
(18). It is therefore important to understand why 
natriuretic peptides in cirrhotic patients may be 
elevated. Plasma levels of natriuretic peptides are 
elevated relative to healthy controls and are di-
rectly correlated with the extent of liver disease 
(38). Elevations are greater in patients with asci-
tes, spontaneous bacterial peritonitis, and hepatic 
encephalopathy, again reflecting extent of cir-
rhosis (39). Correlations of peptide elevation and 
cirrhosis stage may reflect impaired ability of the 
cirrhotic liver to clear these peptides, although the 
exact contribution of hepatic clearance is unknown 
(40). Interestingly, individual studies in our anal-
ysis reported higher MELD scores in those with 
greater levels of BNP–NT-BNP, again suggesting 
the correlation of cirrhosis severity with biomarker 
elevation. It should be noted that patients with 
acute liver failure were excluded from most of our 
included studies, and the implications of peptide 
measurement in that population are unknown.
Biomarker elevations are also seen in sepsis, 
renal insufficiency, and pulmonary hypertension 
with implications for hepato-renal and hepato-
pulmonary syndrome (41). Studies in our analysis 
commented very infrequently on sepsis, renal in-
sufficiency, or pulmonary disease, and we do not 
know whether these factors may have confounded 
peptide levels or mortality rates. Natriuretic peptide 
levels are also decreased by diuretic or aldosterone 
antagonist use, which a large number of cirrhotic 
patients use (19). A large number of patients in our 
analysis used diuretics, aldosterone antagonists, or 
both before to transplantation. Whether decreases 
in BNP–NT-BNP in patients on these medications 
confounded results of our analysis is again un-
known and requires further investigation.
Cardiac mechanisms for B-type peptide 
alterations in cirrhotic patients
Traditional cardiac disease may also account for 
elevations in natriuretic peptides. Advances in 
care are leading to an older transplant population 
with a greater number of comorbidities, including 
ischemic cardiac disease (42). In addition, NASH 
is on track to become the most common indication 
for liver transplantation (43). Presence of NASH 
is associated with hyperlipidemia, hypertension, 
diabetes, and coronary artery disease (44,45). Pa-
tients with NASH experience a greater number of 
adverse cardiac events than those without NASH, 
and this is likely attributable to underlying isch-
emic heart disease (46). In our analysis, NASH 
accounted for only 5% of transplant indications 
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comorbid ischemic or non-ischemic heart disease 
were sparsely reported in our study population 
and could certainly have contributed to biomarker 
elevation. Ischemic and non-ischemic heart disease 
confer peri-operative risk and remain an essential 
component of the pre-liver transplant workup (47).
Last, CCM itself results in elevation of natri-
uretic peptides (2). Echocardiographic measure-
ments demonstrate diastolic dysfunction and 
increased ventricular chamber thickness in those 
with CCM and biomarker elevation (10). A high 
frequency of cirrhotic patients display cardiac 
abnormalities such as cardiomegaly and left ven-
tricular hypertrophy in autopsy studies (48). It is 
thought that splanchnic vasodilation leads to in-
creases in cardiac output and heart rate, resulting 
in ventricular thickening and biomarker elevation 
(2). Indeed, BNP–NT-BNP levels are greater in cir-
rhotic patients who display systolic dysfunction 
and have a direct correlation with long-term sur-
vival (8). Whether or not CCM itself conveys peri-
operative risk is not established. In our analysis, 
only the study by Bernal et al excluded those with 
prior cardiac disease (29). Future studies that ex-
amine non-operative and operative outcomes in 
patients with CCM but no signs of other cardiac 
disease will help establish the clinical significance 
of this condition.
Optimizing test parameters in cirrhotic patients 
and liver transplantation
The use of BNP–NT-BNP as a pre-operative risk 
assessment tool has recently been introduced 
into the Canadian Cardiovascular Society’s peri-
operative guidelines (49). This recommendation 
is largely based on one high-quality analysis (20). 
This analysis shows that a pre-operative BNP more 
than 92 pg/mL or NT-BNP more than 300 pg/mL 
in patients at elevated risk for cardiac disease (aged 
65 years or older, Revised Cardiac Risk Index ≥ 1, 
or ages 45–64 years with significant cardiovascular 
disease) effectively identified patients at higher risk 
for peri-operative cardiac events. These patients are 
then subsequently monitored with post- operative 
serial troponin measurements. An elevation in tro-
ponin may result in initiation of acetylsalicylic acid, 
a statin, and an angiotensin-converting enzyme in-
hibitor or angiotensin receptor blocker (49).
The analysis by Rodseth et al did not include 
any studies of liver transplantation, and the preva-
lence of cirrhotic patients was not reported (20). 
Whether the discriminatory thresholds calculated 
in that study are applicable to cirrhotic patients or 
liver transplantation is unknown. Discriminatory 
thresholds for BNP and NT-BNP in our included 
studies appear to be higher than those recom-
mended in the Canadian Cardiovascular Society 
guidelines. This may reflect non-cardiac mecha-
nisms of peptide elevation in cirrhotic patients. In 
addition, the study by Toussaint et al found that 
BNP values above or below the discriminatory 
threshold (155 pg/mL) were better at predicting 
ICU mortality or survival in those patients with a 
MELD score of more than 25 (23). Taken together, 
these data suggest that both optimization of dis-
criminatory thresholds and addition of parameters 
unique to cirrhotic patients, such as MELD scores, 
will help to create a more reliable method of risk 
stratification for liver transplantation.
Role of cirrhotic cardiomyopathy in risk 
stratification
As discussed earlier, etiology of cardiac disease in 
cirrhotic patients includes traditional ischemic and 
non-ischemic heart disease but also CCM. The peri-
operative risk of traditional cardiac disease is well 
established, but the clinical significance of CCM re-
mains debated. At the current time, the American 
Association for the Study of Liver Diseases prac-
tice guidelines and American Heart Association 
guidelines for kidney and liver transplant candi-
dates recommend assessment for coronary artery 
disease before surgery, but neither make any men-
tion of CCM (47,50). Although increased rates of 
cardiac events in the cirrhotic population, even in 
the absence of known cardiac disease, argues for 
CCM as a significant entity, this must be confirmed 
through future studies.
Limitations
Limitations of this meta-analysis included that only 
a small number of studies were identified, varying 
BNP assays were used with different cut-offs and 
measurement timing in each study, and there was 
absence of complete clinically relevant information 
such as demographic and echocardiographic data
CONCLUSION
Our analysis suggests that early BNP measure-
ment provides valuable data on post-operative 
mortality in patients undergoing liver transplan-
tation. These data are in agreement with previ-
ous guidelines for other surgical procedures. Risk 
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However, it is important to note that this analy-
sis included a limited number of studies with the 
limitations previously noted. Our results are ex-
ploratory and should be further assessed through 
larger, prospective trials. Future studies may also 
focus on optimization of BNP–NT-BNP discrimi-
natory thresholds and addition of cirrhosis-unique 
parameters to risk scores (e.g., MELD).
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